David M Jackman
ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David M Jackman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04439331 · Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT04439331
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT04439331
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:10 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- 964 citationsRCR 27.6
- Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol · 2007261 citationsRCR 5.8
- New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.AJR Am J Roentgenol · 2010173 citationsRCR 4.4
- A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.Clin Cancer Res · 201698 citationsRCR 3.2
- A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.Oncotarget · 201588 citationsRCR 2.9
- Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.Cancer · 200882 citationsRCR 1.8
- Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.Lung Cancer · 201357 citationsRCR 1.5
- Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.Oncologist · 201948 citationsRCR 1.6
- 43 citationsRCR 1.1
- 25 citationsRCR 0.7